1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Suicide Risk: new trials by email Literature Review of Suicide Risk trials Research Report on Suicide Risk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial Suvorexant (dual orexin receptor antagonist) - Suicide Risk, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Marianne Goodman | 30 | 2025-09-01 | 2025-09-25 |
Depressive Disorder, Major (1)
Depressive Disorder (1) · Mental Disorders (1) · Mood Disorders (1)
Orexin Receptor Antagonists (1) · suvorexant (1)
Marianne Goodman (1)
United States (1)